Vanda Pharmaceuticals leans heavily on a small set of medicines just as one of its key products faces cheaper copycat competition, putting its sales and profits under pressure. New drug candidates and expansion plans could help, but high development costs, slow approvals, and tougher pricing rules may make the path bumpier than it looks.Read more
Vanda Pharmaceuticals is pushing new and expanded medicines in brain and nerve conditions, aiming to replace slowing sales from older drugs and build a steadier long-term business. The big question is whether new approvals and launch momentum arrive fast enough to offset copycat competition, rising spending, and tough insurer negotiations.Read more
Key Takeaways Fanapt and Bysanti launches are set to deliver rapid, sustained revenue growth and significant margin improvement due to expanded prescriber engagement and high-margin patient transitions. Diversified late-stage pipeline and scalable commercial platform drive multi-year revenue resilience, with focus on specialty therapies providing durable margins and global market access.Read more
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company’s products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
